Document Page: First | Prev | Next | All | Image | This Release | Search
File: 121096_sep96_decls13_0002.txt
Subject: NSN 6305 01 178 7903 PYRIOSTIGMINE BROMIDE TABLETS 30 MG
Unit: OTSG
Parent Organization: HSC
Box ID: BX003203
Folder Title: NSN 6505-01-178-7903 PYRIDOSTIGMINE BROMIDE TABLETS
Document Number: 1
Folder Seq #: 117
DEIARTMENT OF HEALTH& HUMAN SERVICES Public Health S*Nke
Food and Drug Adminis
tration
Rockville MD 20857
December 5, 1983
omurphy A. Chesney
Major General# USArg Mc
Deputy Surgeon General
Department of the Air
Force
Headquarterst United States AirForce
Bolling APBE D. C. 20332
Dear General Chesneyl
Your July 20, 1983 letter to me requested that the Food
and Drug Administration (FDA) review a package of data
relating to the wartime use of pyridostigmine bromide
tablets as a nerve agent antidote. My October 26,'1983
letter to you provided the report of FDA's evaluation of
the data. Members of your staff met with FDA on October
28, 1983 to discuss the results of IPDA's eval%)@ion. 1
was unable to attend that meeting because of a prior
commitment, but Mr. Paul F. Vogel of my staff informed
me that the dialogue proved very useful# by clarifying
and satisfying some concerns on the part of both the Air
Force and FDA that arose from LPI)A'S evaluation of the
data. Dr. Robert Temple modified one of the conclusions
contained in his original evaluation report, based on
discussions with your representatives during this
meeting. Mr. Vogel furnished a copy of the modified
original evaluation report to Major Tom Smogur. I am
enclosing a copy of Mr. Vogells memorandum of the
meeting.
When Colonel Jack Moll and Major Smogur delivered your
origi'nal letter with accompanying data to me on July 21,
1983# we briefly discussed the Air Force's plan to
deploy pyxidostigmine bromide tablets at various
overseas locations throughout the world for controlled
storage, to be available in time of war for distribution
and use by military personnel. our discussion included
the position FDA might take regarding storage of the
drug within the United states. i have discussed the
matter with the Commissioner and the Associate
commissioner for Regulatory Affairs. The Commissioner
confirms"that the rDAi-,would-Fnotiobjectmt@cQntr Iled
t@agf!lof@tbt;@prod!jc -uo&,Lby- ilitary
q_ - -1 _tdomestically,@for-@ _.m
pi4Kq-qnnel-unde@.,,the,77oamo-,contingency-,Gituations-.@-asr.yoii
ar@planning-@,-fpr-.-overs*as.-@,to the extent domestic
availability might be necessary for national security
reasons,
Document Page: First | Prev | Next | All | Image | This Release | Search
Document 3 f:/Week-36/BX003203/NSN 6505-01-178-7903 PYRIDOSTIGMINE BROMIDE TABLETS/nsn 6305 01 178 7903 pyriostigmine bromide table:12069615355114
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = NSN 6505-01-178-7903 PYRIDOSTIGMINE BROMIDE TABLETS
Folder Seq # = 117
Subject = NSN 6305 01 178 7903 PYRIOSTIGMINE BROMIDE TABLE
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 06-DEC-1996